Healthy Subjects
Conditions
Keywords
Healthy Subjects, Device, PK, Phase 1, Bioequivalence, Adalimumab, Single Dose
Brief summary
This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
Interventions
DEVICEPF-06410293 PFS
PF-06410293 40 mg administered subcutaneously by Prefilled syringe
DEVICEPF-06410293 PFP
PF-06410293 40 mg administered subcutaneously by prefilled pen
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy female subjects and/or male subjects, who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and pulse rate measurement, 12 lead electrocardiogram (ECG), and clinical laboratory tests. 2. Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 pounds). 3. Chest X ray with no evidence of current, active TB or previous (inactive) TB, fungal or general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 24 weeks prior to Day 1 and read by a qualified radiologist. 4. Female subjects of non childbearing potential must meet at least one of the following criteria: a. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed by having a serum follicle stimulating hormone (FSH) level confirming the post menopausal state; b. Have undergone a documented hysterectomy and/or bilateral oophorectomy; c. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) will be considered to be of childbearing potential.
Exclusion criteria
1. Evidence or history of clinically significant infectious, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, autoimmune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). 2. Evidence or history of nervous system demyelinating diseases (including multiple sclerosis, optic neuritis, Guillain Barré syndrome). 3. History of relevant orthostatic hypotension, fainting spells or blackouts. 4. Previous history of cancer, except for adequately treated basal cell or squamous cell carcinoma of the skin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum serum concentration (Cmax) | Day 1 - Day 15 |
| Area under the concentration curve (AUC 0-2wk) | Day 1-Day 15 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to reach the maximum serum concentration (Tmax) | Day 1 - Day 43 | — |
| AUC from time 0 to the last time point with quantifiable concentration (AUCT) | Day 1 - Day 43 | — |
| AUC extrapolated to infinity (AUC0 inf) | Day 1 - Day 43 | — |
| Injection site tolerability (Subject Assessment - Visual Analog Scale) - Mean Injection site pain over 24 hour period post dose | Hour 0 (immediately after injection), 15 minutes, 1, 3, 8, 12 and 24 hours post injection | Mean injection site pain over a 24 hour period post dose rated by subject on a visual analog scale (VAS), compared for injection by PFS or PFP, and for the 2 injection locations using each device |
| Apparent clearance (CL/F) | Day 1 - Day 43 | — |
| Terminal half life (t1/2) | Day 1 - Day 43 | — |
| Volume of distribution (Vz/F), | Day 1 - Day 43 | — |
| Injection site tolerability (Blinded Safety Assessor - Modified Draize Scale) - Mean injection site tolerability over 24 hour post dose | 1, 3, 8, 12 and 24 hours post injection | Mean injection site tolerability using the Modified Draize Scale Numerical Grade over 24 hours post dose rated by the blinded Safety Assessor, compared for injection by PFS or PFP, and for the 2 injection locations using each device |
Countries
United States
Outcome results
None listed